0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
76
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Menopause

Conditions

Menopause, Menopausal Vasomotor Symptoms

Trial Timeline

May 28, 2004 โ†’ May 4, 2005

About 0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo

0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA) + 0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA) + placebo is a phase 3 stage product being developed by Novo Nordisk for Menopause. The current trial status is completed. This product is registered under clinical trial identifier NCT00184795. Target conditions include Menopause, Menopausal Vasomotor Symptoms.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT00184795Phase 3Completed

Competing Products

20 competing products in Menopause

See all competitors